The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Glucagon-like peptide-1 (GLP-1) receptor agonists ... “CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. Novo ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

GLP-1 agonists (also called GLP-1 receptor agonists or GLP-1 analogues) are usually injectable medications that help manage blood sugar levels in people with type 2 diabetes. They do this by ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon ... oxyntomodulin analog (OPK-88006) with ...

between dosed animals and control animals (Table 1). There were no histological signs of pancreatitis in any repeat-dose toxicity studies in rats. PCNA staining indicated cell proliferation within ...

Unlike many oral small-molecule GLP-1 therapies being developed—whose compounds are almost exclusively modified analogs of existing molecules such as Pfizer's Danuglipron and Eli Lilly's ...

(RTTNews) - OPKO Health (OPK) and Entera Bio (ENTX), Monday announced a collaboration to develop the first oral dual GLP-1/glucagon peptide ... acting oxyntomodulin analog or OPK-88006 with ...

Other advantages of the HALO technology platform and long-acting subcutaneous GLP-1 RA MET ... acting amylin analog MET-233i drug it is working on evaluating in a phase 1 study.